NEW YORK (GenomeWeb News) – Roche Diagnostics today said that it has signed a memorandum of understanding to collaborate with China's CapitalBio on developing molecular diagnostics applications and technologies to serve unmet needs of researchers worldwide.
Specifically, the alliance aims to further develop microarray technologies and complementary products for molecular diagnostics applications. The initial focus will be on enhancing and automating the Roche NimbleGen microarray workflow for preventive and personalized diagnostics, said Roche.
The firms also plan to cooperate on education efforts on the benefits and use of molecular diagnostics that exploit technologies such as microarrays and Roche 454 Life Sciences' next-generation sequencing products in China and international markets. According to Fatt-Heng Wong, GM of Roche Diagnostics Shanghai, the firms also plan to cooperate in marketing products in the greater China and international markets.
Financial and other terms of the alliance were not disclosed.
CapitalBio already serves as certified service provider of NimbleGen products. The firm operates a medical testing lab in Chengdu and a microarray genomics service facility at its headquarters in Beijing.